Condition: Neuroendocrine Tumor · Liver Metastases · Neuroendocrine Gastroenteropancreatic Tumour · Sponsor: University Hospital, Bordeaux
The management of liver metastases in neuroendocrine neoplasms is challenging. Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs (SSA) is one of the most promising therapeutic options. As liver is the most frequent site of metastatic disease, our project proposes to compare administration of radiolabeled SSA by arterial intrahepatic infusion (experimental approach) vs intravenous administration (conventional). Evaluation will be made by (i) comparing 68Ga-DOTA-peptides uptake after intra-hepatic versus intravenous route (imaging), (ii) by evaluating the safety of an additional intra-hepatic administration of therapeutic radiolabeled SSA (therapy).
This description comes directly from the study's public registry record.
Ghoufrane TLILI, Dr · 05 57 65 64 08 · ghoufrane.tlili@chu-bordeaux.fr
Macary Guillaume · 05 57 62 32 52 · guillaume.macary@chu-bordeaux.fr
Always discuss trial participation with your own doctor first.
| Institut Bergonié | Bordeaux, France | Not Yet Recruiting |
| Institut de cancérologie du Gard (ICG) - CHU de Nîmes | Nîmes, France | Not Yet Recruiting |
| CHU Bordeaux - Hôpital Haut Lévêque | Pessac, France | Recruiting |
| Institut universitaire du cancer de Toulouse (IUCT) Oncopole | Toulouse, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04837885